Unicycive Therapeutics Receives FDA Complete Response Letter On Its Application For Oxylanthanum Carbonate For Hyperphosphatemia In Patients With Chronic Kidney Disease On Dialysis; Letter Relates To Deficiencies Previously Identified At Third-Party Manufacturing Vendor